Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Semler Scientific, Inc. approved a strategic realignment that includes reducing its workforce by approximately 37% and cutting other operating expenses. The company expects the headcount reduction to lower quarterly operating expenses by about $0.7 million to $1.1 million in base salary, with savings beginning in January 2026.
Semler Scientific estimates it will incur about $1.2 million of severance costs from one-time termination benefits, to be paid in December 2025 and January 2026. In parallel, it has adopted a time-based cash retention program for remaining non-executive employees, designed to maintain clinical, regulatory, technical, and operational support, with an estimated cost of $1.6 million.
The company also notes that it is being acquired by Strive, Inc. in an all-stock transaction under a previously announced merger agreement and is providing supplemental information about Strive in an exhibit incorporated by reference. Management cautions that expected cost savings and charges from these actions are subject to risks and uncertainties, and actual results may differ materially.
Semler Scientific, Inc. filed a communication noting that its Director of Bitcoin Strategy retweeted posts about a proposed acquisition of Semler Scientific by Strive, Inc.. The companies explain that Strive has filed a Form S-4 registration statement with the SEC to register Strive Class A common stock to be issued in connection with the proposed transaction, which includes an information statement, proxy statement and prospectus.
Semler Scientific stockholders will receive a definitive information statement/proxy statement/prospectus to vote on the proposed acquisition, and investors are urged to read the SEC materials because they contain important details about both companies and the deal. The text clarifies that this communication is not an offer to sell or buy securities and includes extensive cautionary language about forward-looking statements, emphasizing that actual results may differ materially due to various risks and uncertainties.
Strive, Inc. has filed a communication related to its proposed business combination with Semler Scientific, Inc.. The message emphasizes that any statements about expected strategic or financial benefits, future performance, or the timing and integration of the combined company are forward-looking and subject to significant risks and uncertainties, which could cause actual results to differ materially.
Strive has filed a Form S-4 Registration Statement to register Class A common stock to be issued in the transaction, which will include an Information Statement/Proxy Statement/Prospectus sent to Semler Scientific stockholders to seek approval of the deal. Investors are directed to review the Form S-4, related proxy materials, and each company’s SEC filings for detailed information. The communication also clarifies that it does not constitute an offer to sell or buy securities, nor a solicitation of any vote or approval, and that any offer will only be made through a compliant prospectus or applicable exemption.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific, Inc.. The notice emphasizes that many statements about the deal and the future performance of the combined company are forward-looking and subject to significant risks and uncertainties, so actual results may differ materially from expectations.
Strive explains that it has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction, which includes an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive. Semler Scientific stockholders will receive these materials to consider and vote on the proposed transaction. The communication also identifies that directors, officers and employees of both companies may be deemed participants in the proxy solicitation and directs investors to SEC filings and company investor relations websites for detailed ownership and governance information.
Strive, Inc. uses this communication to promote its proposed business combination with Semler Scientific, Inc. (SMLR) and to explain its bitcoin treasury and financing strategy. CEO Matt Cole describes Strive as a pure-play bitcoin treasury company that aims to outperform bitcoin over the long term by using “digital credit,” primarily perpetual preferred equity, rather than debt. He highlights Strive’s first preferred equity product, SATA, a perpetual, variable-rate preferred that raised about $160 million on $200 million notional at 80, was upsized from an initial target and was reported as about twice oversubscribed. Cole contrasts Strive’s structure—no debt and unencumbered bitcoin—with MicroStrategy’s long-term goal of becoming “pref only,” positioning Strive as already operating with that target capital structure. He also frames the pending Semler merger as a way to add roughly 5,000 bitcoin and an operating business that Strive expects to monetize over time, while emphasizing that the transaction remains subject to stockholder approval and regulatory review.
Strive, Inc. has filed a Registration Statement on Form S-4 with the SEC to register Class A common stock that will be issued in its proposed business combination with Semler Scientific, Inc. The Form S-4 includes an information statement for Strive, a proxy statement for Semler Scientific stockholders, and a prospectus for Strive. A definitive combined Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval of the transaction.
The communication emphasizes that many statements about the expected benefits, timing, and integration of the proposed transaction are forward-looking and subject to significant risks and uncertainties. Investors are urged to read the Form S-4, the Information Statement/Proxy Statement/Prospectus, and related SEC filings for detailed information about Strive, Semler Scientific, and the proposed transaction.
Semler Scientific and Strive share a long-form discussion outlining Strive’s Bitcoin-focused treasury model and its proposed business combination with Semler Scientific. Strive’s CIO describes using Bitcoin as a core balance-sheet asset, targeting long-term compounding in response to perceived monetary debasement and liquidity cycles.
The talk highlights Strive’s choice to avoid restrictive convertible debt, instead raising about $750 million of equity via a PIPE plus $750 million of traditional warrants, and later issuing a $200 million perpetual preferred stock called SATA with a stated 12% dividend. Management says Strive holds over 7,500 Bitcoin and that acquiring Semler could add more than 5,000 additional Bitcoin. They emphasize a simple capital structure with no debt, only common equity and perpetual preferred, and frame SATA as “digital credit” designed for yield-focused investors while common stock targets those seeking amplified Bitcoin exposure.
Strive, Inc. released a communication about its proposed business combination with Semler Scientific, Inc., focusing on legal and procedural information rather than deal terms. It explains that many statements about the transaction and the future performance of the combined company are forward-looking and subject to significant risks and uncertainties, referring investors to recent Form 10-Q filings and Strive’s Form S-4 for more detail. Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction, which includes an information statement for Strive, a proxy statement for Semler Scientific and a prospectus for Strive. Semler Scientific stockholders will receive a definitive Information Statement/Proxy Statement/Prospectus to vote on the transaction, and investors are directed to obtain SEC filings for complete information. The communication also clarifies that it is not an offer to sell securities or a solicitation of any vote or purchase.
Semler Scientific CEO Douglas Murphy-Chutorian reported stock option activity and share sales. On 11/17/2025 he exercised a stock option to acquire 125,000 shares of Semler Scientific common stock at an exercise price of $2.23 per share. He then sold 57,669 shares at a weighted average price of $20.09 and 12,737 shares at a weighted average price of $20.73, with the filing stating that these sales were made to cover the option exercise price and withholding taxes. The filing also shows a transfer of 54,594 shares from direct ownership to a family trust and a corresponding 54,594-share increase in indirect ownership. After these transactions, Murphy-Chutorian reports beneficial ownership of 241,303 shares held indirectly through a family trust over which he and his spouse share voting and investment power.
Strive, Inc. released a Rule 425 communication regarding its proposed business combination with Semler Scientific. The message, posted by Strive’s CEO on X, reiterates cautionary forward‑looking statements.
Strive has filed a Registration Statement on Form S-4 to register the Class A common stock to be issued in connection with the transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. Investors are urged to read these materials when available on the SEC’s website. The communication also states it is not an offer to sell or solicit the purchase of securities.